Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000379331 | SCV000335435 | uncertain significance | not provided | 2015-09-29 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000260746 | SCV000402004 | uncertain significance | Peroxisome biogenesis disorder 1A (Zellweger) | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000667830 | SCV000792335 | uncertain significance | Peroxisome biogenesis disorder type 3B; Peroxisome biogenesis disorder 3A (Zellweger) | 2017-06-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002521897 | SCV003459559 | uncertain significance | Peroxisome biogenesis disorder 3A (Zellweger) | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 117 of the PEX12 protein (p.Ile117Val). This variant is present in population databases (rs767207001, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with PEX12-related conditions. ClinVar contains an entry for this variant (Variation ID: 283389). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |